Literature DB >> 16804403

Use of antibiotics in the treatment of inflammatory bowel disease.

Molly Perencevich1, Robert Burakoff.   

Abstract

An increasing amount of evidence suggests that enteric flora may have a role in the pathogenesis of inflammatory bowel disease (IBD). Patients with IBD appear to have an altered composition of luminal bacteria that may provide the stimulus for the chronic inflammation characterizing IBD. The suspected role of bacteria in the pathogenesis of IBD provides the rationale for using agents, such as antibiotics, that alter the intestinal flora. However, there remains much uncertainty about the optimal use of antibiotics in the treatment of Crohn's disease, ulcerative colitis, and pouchitis. This article reviews the literature and presents a clinical model for the use of antibiotics in IBD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16804403     DOI: 10.1097/01.MIB.0000225330.38119.c7

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  30 in total

1.  Prolonged antibiotic use induces intestinal injury in mice that is repaired after removing antibiotic pressure: implications for empiric antibiotic therapy.

Authors:  Lindsey E Romick-Rosendale; Anne Legomarcino; Neil B Patel; Ardythe L Morrow; Michael A Kennedy
Journal:  Metabolomics       Date:  2014-02       Impact factor: 4.290

Review 2.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 3.  Microbial host interactions in IBD: implications for pathogenesis and therapy.

Authors:  R Balfour Sartor; Marcus Muehlbauer
Journal:  Curr Gastroenterol Rep       Date:  2007-12

Review 4.  Medical and Surgical Management of Pediatric Ulcerative Colitis.

Authors:  José M Cabrera; Thomas T Sato
Journal:  Clin Colon Rectal Surg       Date:  2018-02-25

Review 5.  Inflammatory bowel disease in the dog: differences and similarities with humans.

Authors:  Matteo Cerquetella; Andrea Spaterna; Fulvio Laus; Beniamino Tesei; Giacomo Rossi; Elisabetta Antonelli; Vincenzo Villanacci; Gabrio Bassotti
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

6.  Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis.

Authors:  Keqiang Chen; Mingyong Liu; Ying Liu; Teizo Yoshimura; Wei Shen; Yingying Le; Scott Durum; Wanghua Gong; Chunyan Wang; Ji-Liang Gao; Philip M Murphy; Ji Ming Wang
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

Review 7.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis.

Authors:  Ryan Ungaro; Masayuki Fukata; David Hsu; Yasmin Hernandez; Keith Breglio; Anli Chen; Ruliang Xu; John Sotolongo; Cecillia Espana; Julia Zaias; Greg Elson; Lloyd Mayer; Marie Kosco-Vilbois; Maria T Abreu
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-09       Impact factor: 4.052

9.  Variation in Antibiotic Use for Children Hospitalized With Inflammatory Bowel Disease Exacerbation: A Multicenter Validation Study.

Authors:  Matthew P Kronman; Jeffrey S Gerber; Priya A Prasad; Amanda L Adler; Julie A Bass; Jason G Newland; Kavisha M Shah; Danielle M Zerr; Rui Feng; Susan E Coffin; Theoklis E Zaoutis
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-03       Impact factor: 3.164

Review 10.  Crohn's disease: a review of current treatment with a focus on biologics.

Authors:  Julián Panés; Fernando Gomollón; Carlos Taxonera; Joaquin Hinojosa; Juan Clofent; Pilar Nos
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.